Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Henrik Tang Vestergaard"'
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 4, Pp 652-664 (2020)
Drug development guidelines from regulatory authorities provide important information to sponsors on requirements for clinical evidence needed to support approval of new drugs. In the field of Alzheimer’s disease (AD), recently published guidelines
Externí odkaz:
https://doaj.org/article/a67c500279614ef79f81ecf95f5c2079
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 4, Pp 361-370 (2019)
For regulatory approval of a new medicine, the gold standard for demonstration of efficacy has traditionally been a minimum of two positive, adequate, and well‐controlled clinical trials. Nevertheless, drugs to treat cancer and rare diseases are us
Externí odkaz:
https://doaj.org/article/5c742bd3825e4803aa3a267aaa370037
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Neurodegenerative disorders are characterized by progressive degeneration of nerve cells resulting in functional decline of cognition and/or movement. As the prevalence of many of these disorders increases with the aging global population, there is a
Externí odkaz:
https://doaj.org/article/0cdb79c28a5649f8bfd0f3af2eb5c695
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 4, Pp 652-664 (2020)
Clinical and Translational Science
Clinical and Translational Science
Drug development guidelines from regulatory authorities provide important information to sponsors on requirements for clinical evidence needed to support approval of new drugs. In the field of Alzheimer's disease (AD), recently published guidelines a
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 12, Iss 4, Pp 361-370 (2019)
Clinical and Translational Science, Vol 12, Iss 4, Pp 361-370 (2019)
For regulatory approval of a new medicine, the gold standard for demonstration of efficacy has traditionally been a minimum of two positive, adequate, and well‐controlled clinical trials. Nevertheless, drugs to treat cancer and rare diseases are us
Publikováno v:
Clinical Pharmacology & Therapeutics. 104:169-177
A minimum of two positive, adequate, and well-controlled clinical trials has historically been the gold standard for providing substantial evidence to support regulatory approval of a new medicine. Nevertheless, the present analysis of European Marke
Publikováno v:
Molecular Therapy. 21(9):1644-1648
Advanced therapy medicinal products (ATMPs) comprise gene therapy medicinal products (GTMPs), somatic cell therapy medicinal products (CTMPs), and tissue-engineered products (TEPs). So-called combined ATMPs incorporate one or more medical devices as
Publikováno v:
Journal of Pharmacy and Pharmacology. 64:1523-1548
ObjectivesThis review provides an overview of intestinal human transporters for organic anions and stresses the need for standardization of the various in-vitro methods presently employed in drug–drug interaction (DDI) investigations.Key findingsCu
Autor:
Povl Krogsgaard-Larsen, Bente Frølund, Tine B. Stensbøl, Anne T Jørgensen, Connie Sanchez, Lena Tagmose, Tommy Liljefors, Christine Engblom, Henrik Tang Vestergaard, Uffe Kristiansen
Publikováno v:
Journal of Medicinal Chemistry. 45:2454-2468
A number of analogues of the low-efficacy partial GABA(A) agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABA(A) receptor ligands.